The Retinal Renin-Angiotensin-Aldosterone System: Implications for Glaucoma

Area of Science:

• Ophthalmology
• Endocrinology
• Cardiovascular Biology

Background:

• The renin-angiotensin-aldosterone system (RAAS) is crucial in cardiovascular and renal health.
• Emerging evidence indicates an active local RAAS within the human eye.
• Aldosterone's role in hypertension and cardiovascular/renal diseases is well-established.

Purpose of the Study:

• Investigate the role of the local RAAS in retinal ischemia-reperfusion (I/R) injury.
• Explore the link between aldosterone and glaucoma pathogenesis, particularly normal-tension glaucoma (NTG).
• Identify potential therapeutic targets for NTG.

Main Methods:

• Assessed upregulation of angiotensin II type 1 receptor (AT1-R) post-retinal I/R injury.
• Measured reactive oxygen species (ROS) production and NADPH oxidase pathway involvement.
• Evaluated the effect of AT1-R antagonists on retinal ROS and NADPH oxidase expression.
• Studied the impact of aldosterone administration on retinal ganglion cell loss and optic nerve degeneration in an animal model.

Main Results:

• Retinal AT1-R protein levels increased 12 hours after I/R injury.
• I/R injury elevated retinal ROS production via NADPH oxidase, preventable by AT1-R antagonists.
• Aldosterone administration induced retinal ganglion cell loss and glaucomatous optic nerve damage without elevated intraocular pressure.
• The study suggests a significant role for the local RAAS in retinal ischemic injury pathways.

Conclusions:

• The local RAAS is implicated in retinal ischemic injury.
• Aldosterone contributes to retinal ganglion cell loss and optic nerve degeneration, relevant to glaucoma pathogenesis.
• Further investigation into NTG prevalence in primary aldosteronism patients is warranted.